Status:
UNKNOWN
Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis.
Lead Sponsor:
Sohag University
Conditions:
Polycythemia Vera
Eligibility:
All Genders
18+ years
Brief Summary
Polycythemia vera (PV), a hematological neoplasm characterized by excessive erythropoiesis due to Janus kinase 2 (JAK2)- activating mutations. On the other hand, patients with secondary polycythemia (...
Detailed Description
We will collect data about clinical manifestations at the time of diagnosis, history of thrombosis and investigations as complete blood picture, including Hematocrit and haemoglobin level, serum uric ...
Eligibility Criteria
Inclusion
- All patients aged 18 years and older who were newly diagnosed to have polycythemia vera between September 2014 and November 2022 at Sohag university hospital, department of internal medicine, hematology unit and hematology outpatient clinic.
Exclusion
- Patients were excluded if: (1) their disease was not newly diagnosed, (2) their disease met WHO criteria for chronic, acute myeloid leukemia or other myeloid neoplasms.
Key Trial Info
Start Date :
December 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05993065
Start Date
December 15 2022
End Date
October 1 2023
Last Update
August 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Sohag, Egypt